Neovacs

Grisotech S.a.

Claride Pharma, S.a.

Aileens Pharma S.r.l.

Diopeite Sa

In Fieri S.r.l.

Franzoni Filati S.p.a.

Bernard Bizzini

Daniel Zagury

Jean-François Zagury

Ivo Volpato

Helene Le Buanec

Jean-Fran&ccedil;ois Zagury

Jean-Francedillaois Zagury

Rolando Wyss

Hélène Le Buanec

Jean Francois Zagury

Sonia Longo

Maria Grazia Franzoni

Enore Giovannini

Jean François Zagury

The present invention relates in one aspect to a conjugate of a mucopolysaccharide or mucopolysaccharidic fraction and a cellular wall fragment of a bacterium belonging to thegenus, and in particular to thespecies, also named P40. The conjugate of the invention is applied to medicine, in particular for topical treatment of infections, dermatological affections, such as psoriasis, acne, allergic reactions, such as rashes and eczema, and in vaginal mucosae affections.

Conjugate of a fragment of a cellular wall of a bacterium and a mucopolysaccharidic carrier, and uses in medicine thereof

The invention concerns a pharmaceutical composition comprising, as the active ingredient, human natural antibodies of the IgG isotype, that neutralize the activity of a human cytokine selected from VEGF, IFN&#x3b1;, IL-4, TNF&#x3b1; and TGF&#x3b2;, the said neutralizing antibodies inhibiting at least 50% of the maximum biological activity induced by an amount ranging from 0.006 ng to 0.05 ng of the said cytokine in vitro.

High-yield method for the production of human antibodies blocking the biological activity of a human cytokine

The invention concerns vaccines comprising as an active principle an immunogen which is a cytokinetic factor or a cell regulating factor particularly transcriptional or another type of factor with immunosuppressive/apoptotic/angiogenic properties abnormally released in the extracellular (stromal) environment by cancer or stromal cells of malignant tumors, and a pharmaceutically acceptable carrier for inducing a systemic or mucosal immune response with secretory formation of class IgC or IgA neutralizing antibodies directed against the native factor, or which is derived from such a factor and the use of said immunogen to obtain a medicine for use as anticancer drug.

Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors

The invention relates to an immunogenic or vaccine composition inducing an immune response towards the HPV-16 Papillomavirus native E7 protein, without simultaneously inducing an immunosuppression, said composition comprising, as the active ingredient, a non immunosuppressive mutated E7 protein, comprising the amino acid sequence consisting, from the N-terminal end to the C-terminal end, in:

Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus

The main object of the present invention is to provide polysaccharide-coated antigens derivatised with lectins for pharmaceutical use. In the vaccines, polysaccharides are preferably selected from the group consisting of chitosan, low-molecular-weight and high-deacetylation-degree chitosan, methyl glycol. chitosan, alginic acid, polymannuronic acid and salts or derivatives thereof. In the vaccines of the invention, antigens are microorganisms, infectious agents or constituents thereof, hormones, enzymes, proenzymes, narcotics, bioactive peptides, metabolites, biological precursors, cell constituents, allergens, and the lectins are of vegetable origin.

Vaccines absorbable by the transmucosal way

Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when administrated to a subject in need thereof to treat homeostatic conditions and disorders associated with an overproduction of cytokines.

Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing them

A non-toxic immunogenic compound, which may be administered to humans, is derived from an HIV-1, HIV-2, HTLV-1 or HTLV-2 viral regulatory protein by chemical processing using a coupling agent such as an aldehyde, or from a carrier protein activated by pre-processing using an aldehyde. This compound is capable of being recognized by antibodies to the viral regulatory protein and retains sufficient immunogenic properties to produce antibodies that neutralize or block the native protein, while losing at least 50% of the toxic biological properties of the native protein.

Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them

Non-Toxic immunogens derived from a retroviral regulatory protein,

Inactive but immunogenic cytokines, pharmaceutical compositions

Growing community of inventors

Carcassonne, France

Bernard Bizzini